Drug therapy in hospitalized patients with very severe symptoms following COVID-19

Rohollah Valizadeh1,2, Nahid Dadashzadeh3, Roya Zakeri4, Steven James Kellner5, Mohsen Mohammad Rahimi6*1,2
1Student Research Committee, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
2Nickan Research Institute, Isfahan, Iran
3Legal Medicine Research Center, Iranian Legal Medicine Organization, Tehran, Iran
4Pediatrics Specialist, Tabriz University of Medical Sciences, Tabriz, Iran
5Head International Research and Development, Mesencell Biotech International Ltd, 20-22 Wenlock Road, London, N1 7GU, UK
6Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

*Corresponding author: Mohammad Rahimi, Email: Mohammadrahimi@tbzmed.ac.ir

Drug therapy in COVID-19

To date, there is no antiviral medication or vaccine to treat or prevent coronavirus infection, however; there are some agents to help patients in the process of recovery like broad-spectrum antiviral agents. Various antiviral agents are used extensively to treat coronavirus infection, however the results are not clear, while there was not any drug to be effective against COVID19 (1). After understanding the genome of affected individuals with coronaviruses, the development of new medications may be possible. The crucial drawback is that anti-coronavirus activity of these agents is shown in vitro not in practice (2).

After emerging new version of coronavirus, as the cause of COVID-19, lots of efforts were made to discover efficient medication against this virus in the People’s Republic of China (3). National health commission of this country presented a protocol to treat COVID-19, such as lopinavir/ritonavir named Kaletra as a protease inhibitor (400 mg/100 mg bid), interferon alfa (IFN- alpha) (5 million U bid) as antivirals were recommended in some protocols (4). In the meantime, Kaletra had strange effect to make the coronavirus titer negative or little (5). Additionally, when ribavirin is added to lopinavir/ritonavir, the effect of antivirus activity increases and respiratory symptoms such as severe acute respiratory syndrome (SARS) can be improved in a shorter time (6).

One of the most common drugs which are used to treat COVID-19 in China is oral oseltamivir. Oral oseltamivir was used for treating influenza however there is no strong evidence that oseltamivir can treat COVID-19 (7, 8). Baricitinib is a drug for the treatment of rheumatoid arthritis and accompanied by antiviral drugs plays an effective role in the treatment of COVID-19 (9). Chloroquine phosphate as an old drug for the treatment of malaria was used widely in patients with COVID-19 to treat acute respiratory distress syndrome and had acceptable results in China (10). Additionally, chloroquine or hydroxychloroquine was tested in the pneumonia of COVID-19 and it was useful in shortening the disease period (11). Combination of chloroquine with remdesivir is effective to control the COVID-19 infection in a laboratory situation and has been used in patients with acceptable results (12).

Previously, Savarino et al investigated the effects of chloroquine on viral infections in 2003; showed how the anti-viral and anti-inflammatory activities of
chloroquine may result in controlling COVID-19 disease (13). Furthermore it was administrated for HIV and had powerful antiviral effects (14).

Likewise, the Chinese traditional medicine named Lianhuaxiongwen and Shufeng Jiedu may be effective in the treatment of COVID-19; however, it needs further clinical trials to approve the hypothesis (15). Theoretically, angiotensin-converting enzyme 2 (ACE2)-based peptide inhibitors can be chosen for treating the COVID-19 disease, but its administration also needs strong evidence such as cohort studies (16), while the virus enters the cells via ACE2 receptor; therefore, theoretically blocking this receptor might be effective

In summary, the first choice should be antiviral drugs and in some conditions a small dose of safe anti-inflammatory drugs to reduce inflammation. In this regard, chloroquine has both features including antiviral activity and anti-inflammatory effect.

Authors’ contribution
Primary draft was prepared by ND, MMR, and RV. MHR and RV edited the paper. All authors read and signed the final paper.

Conflicts of interest
The authors report no conflict of interests.

Ethical considerations
Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by the authors.

Funding/Support
There was no financial support.

References
1. Kim Y, Liu H, Galasiti Kankanamalage AC, Weerasekara S, Hua DH, Groutas WC, et al. Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor [published correction appears in PLoS Pathog. 2016 May; 12(5):e1005650]. PLoS Pathog. 2016;12:e1005531. doi: 10.1371/journal.ppat.1005531.
2. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15:327-47. doi: 10.1038/nrd.2015.37.
3. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14:69-71. doi: 10.5582/bst.2020.01020.
4. National Health Commission of the People’s Republic of China. Notice on printing and distributing the diagnosis and treatment plan of pneumonia with new coronavirus infection (trial version 3). http://www.nhc.gov.cn/zyjggb/s7653p/202001/f492c9153ea9437bb587ce2fcb7e9a.shtml. Accessed January 23, 2020. (Chinese).
5. Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020;35:e79. doi: 10.3346/jkms.2020.35.e79.
6. Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11:1-4. doi:10.1038/s41467-019-13940-6.
7. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-13. doi: 10.1016/S0140-6736(20)30211-7.
8. Chow EJ, Doyle JD, Uyeki TM. Influenza virus-related critical illness: prevention, diagnosis, treatment. Crit Care. 2019;23:214. doi: 10.1186/s13054-019-2491-9.
9. Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020. doi:10.1016/S1473-3099(20)30132-8.
10. Audio transcript of the news briefing held by the State Council of China on February 17, 2020. The National Health Commission of the People’s Republic of China. http://www.nhc.gov.cn/xcs/yqfkdt/202002/f12a62d10c2a48c6895cedf2f300af7.shtml. Accessed February 18, 2020. (Chinese).
11. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14:72-73. doi:10.5582/bst.2020.01047.
12. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269-71. doi: 10.1038/s41422-020-0282-0.
13. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003; 3:722-727.
14. Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents. 2007; 30:297-308. doi: 10.1016/j.ijantimicag.2007.05.015.
15. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Bioscience trends. 2020;14:69-71.
16. Liu W, Morse JS, Lalonde T, Xu S. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. Chemicochem. 2020. doi:10.1002/cbic.202000047.